About protalix biotherapeutics - PLX
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
PLX At a Glance
Protalix Biotherapeutics, Inc.
2 University Plaza
Hackensack, New Jersey 07601
| Phone | 1-201-696-9345 | Revenue | 52.74M | |
| Industry | Pharmaceuticals: Major | Net Income | -6,604,000.00 | |
| Sector | Health Technology | Employees | 226 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PLX Valuation
| P/E Current | 10.966 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.681 |
| Price to Book Ratio | 3.002 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -29.425 |
| Enterprise Value to Sales | 2.251 |
| Total Debt to Enterprise Value | 0.07 |
PLX Efficiency
| Revenue/Employee | 233,380.531 |
| Income Per Employee | -29,221.239 |
| Receivables Turnover | 5.967 |
| Total Asset Turnover | 0.677 |
PLX Liquidity
| Current Ratio | 2.514 |
| Quick Ratio | 1.544 |
| Cash Ratio | 1.168 |
PLX Profitability
| Gross Margin | 47.846 |
| Operating Margin | -10.428 |
| Pretax Margin | -10.632 |
| Net Margin | -12.521 |
| Return on Assets | -8.48 |
| Return on Equity | -14.444 |
| Return on Total Capital | -11.678 |
| Return on Invested Capital | -12.898 |
PLX Capital Structure
| Total Debt to Total Equity | 17.253 |
| Total Debt to Total Capital | 14.714 |
| Total Debt to Total Assets | 10.105 |
| Long-Term Debt to Equity | 14.383 |
| Long-Term Debt to Total Capital | 12.267 |